|
Abstract [Objective]To evaluate clinical efficacy of zoledronic acid for the treatment of elderly male pa-tients with primary osteoporosis.[Methods]A total of 76 male patients with primary osteoporosis were ran-domly divided into 2 groups.The control group(n=39)was supplemented with calcium and vitamin D daily, while the treatment group(n=37)was given an intravenous drip infusion of zoledronic acid 5mg once based on the treatment of control group.The changes of bone mineral density and bone metabolism markers of all pa-tients were observed after 1 2 months of follow up.[Results]Bone mineral density of lumbar spine,total hip and femoral neck in treatment group was significantly higher than that in control group.Serum levels of bone metabolism markers such asβ-C-terminal telopeptide of type I collagen(β-CTx),procollagen type I N-terminal propeptide(PINP)and bone-specific alkaline phosphatase(BSAP)in treatment group were significantly lower than those in control group(P<0.05).The incidence of severe adverse reaction in two groups were 24.32%and 23.08% respectively,but there was no significant difference(P >0.05).[Conclusion]Zoledronic acid treatment for 1 year can markedly increase bone mineral density,decrease serum levels of bone metabolism markers and reduce the risk of fracture in elderly male patients with primary osteoporosis.
|
|
|
|
|
|
2014, Vol. 31 
